Abstract
The paper outlines pharmacological characteristics and clinical action of Amisulpryde, a second-generation antipsychotic drug recently registered in Poland. Atypical pharmacological properties of Amisulpryde and results of clinical trials in which its action was compared to that of Haloperidol, Flupentixol and Risperidone indicate its usefulness in schizophrenia, both acute and residual. Amisulpryde is the only antipsychotic drug whose effectiveness was evaluated with reference to primary negative symptoms in schizophrenia. Research findings indicate that it is the only medication effectively alleviating these symptoms. Amisulpryde is tolerated well, i.e. it rarely evokes extrapyramidal symptoms and – except for (dose-related) hyperprolactinemia – is free from side effects associated with of many antipsychotic drugs, both classical and of second generation.